Aktienanalyse zu Tempus AI Inc (TEM)TEMTempus AI Inc

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. It operates in the Healthcare sector.

Tempus AI Inc is currently a hold. The stock is priced at $70.93, which is below the average analyst price target of $75 from BofA and $92 from Guggenheim, indicating potential upside. However, the RSI is at 38.335, suggesting that the stock is nearing oversold conditions but still lacks strong momentum. The recent insider selling, with executives selling shares, raises concerns about confidence in the short-term performance, especially with a 5-day change of -7.44%.